Hims & Hers adds Andrew Huberman to board as telehealth group expands into personalized care

Traders Union
All News
Business & Wealth
Companies
Hims & Hers adds Huberman

Highlights

Hims & Hers appointed Andrew Huberman to its board in June 2024, aligning its personalized healthcare expansion with his consumer-health expertise and media reach.
Hims & Hers advances into peptide-based and optimization therapies by acquiring a California peptide facility (February 2025) and planning a dedicated Peptides+ platform pending regulatory approval.
Scicomm Media, Huberman's company, will run podcast ads for Hims & Hers as both parties navigate disclosure, transparency, and potential conflicts amid growing market scrutiny.

Board role deepens ties to Hims strategy

As first reported by Business Insider, Huberman is taking on a broader role at Hims & Hers that goes beyond outside advising, with fiduciary duties on the board as the company builds out its consumer-health platform. He says the move follows six to eight months of discussions with chief executive Andrew Dudum about widening access to more personalized healthcare for consumers who sit between traditional medical systems and high-end concierge care.

Huberman says joining the board gives him a chance to help shape that effort directly rather than only discuss it publicly. Dudum says the company shares Huberman's goal of helping more people take greater control over their health, while Hims & Hers seeks to use its existing scale, nearly 3 million customers, pharmacy capabilities and manufacturing infrastructure to broaden its menu of treatments.

The appointment also links one of the largest audiences in health podcasting to a company that can sell many of the categories he discusses, from hormones to preventive care. Huberman says he will remain free to cover the sector broadly, and says his information will not be filtered differently because of the commercial relationship.

Expansion into peptides raises scrutiny

That independence question is especially important as Hims & Hers pushes into peptide-based and other optimization therapies, areas that remain commercially attractive but scientifically and regulatorily sensitive. The company has already signaled plans for Peptides+, a website section for peptides and other wellness offerings such as NAD+ and vitamin B12, once regulatory approval allows it.

Its peptide strategy predates Huberman's board appointment. Hims & Hers signed a deal for a California peptide facility at the end of 2024, announced the acquisition in February 2025, and by May Dudum was telling investors he was closely tracking peptide innovation for uses including pain management, recovery and longevity.

Huberman says he does not want to encourage broad peptide use among people who do not need it, but he cites Hims & Hers' plan to control manufacturing from start to finish as a key reason for joining. Dudum similarly says the personalized health and longevity market needs to be handled carefully, as telehealth groups, longevity clinics and testing startups compete to turn once-niche services into mainstream consumer offerings.

Huberman Lab's YouTube channel has more than 8 million subscribers, and Huberman's media company, Scicomm Media, is set to run podcast advertisements for Hims & Hers in exchange for payment. He does not specify how individual podcast episodes, social posts or clips will disclose both his board position and separate marketing relationship, leaving investors and consumers to watch how Hims & Hers manages rigor, transparency and commercial influence as it expands.

Earlier, we reported that Chariot Claims raised a $10 million Series A to expand AI-driven case review for consumer disputes.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.